Revlimid with Dexamethasone Approved for Newly Diagnosed Multiple Myeloma

Share this content:
The FDA has expanded indication for Revlimid (lenalidomide) in combination with dexamethasone to include newly diagnosed multiple myeloma.
The FDA has expanded indication for Revlimid (lenalidomide) in combination with dexamethasone to include newly diagnosed multiple myeloma.

Celgene Corporation has announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Revlimid (lenalidomide) in combination with dexamethasone to include patients with newly diagnosed multiple myeloma.

Revlimid in combination with dexamethasone was initially approved by the FDA in 2006 for the treatment of patients with multiple myeloma who have received at least one prior therapy.

“The approval of REVLIMID as an option for use in all patients with multiple myeloma represents a new paradigm in the management of this disease,” said Kenneth Anderson, M.D., Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber/Brigham and Women's Cancer Center.

“We now have clinical evidence demonstrating that starting and keeping newly diagnosed multiple myeloma patients on REVLIMID significantly improves progression-free survival.”

The FDA's approval was based on results from the phase III FIRST trial, which evaluated continuous Revlimid in combination with dexamethasone until disease progression compared with a combination of melphalan, thalidomide, and prednisone in 1,623 patients with newly diagnosed multiple myeloma who were not eligible to receive stem cell transplantation.

RELATED: Ixazomib Improves Progression-Free Survival in Relapsed, Refractory Multiple Myeloma

Results showed a median progression-free survival of 25.5 months in the continuous group compared with 21.2 months in those who received melphalan, prednisone, and thalidomide (HR = 0.72; P = 0.0001). The median overall survival 58.9 months in the Revlimid group versus 48.5 months in the melphalan group (HR = 0.75; 95% CI: 0.62 - 0.90).

Patients in the continuous Revlimid arm also had a 25% risk reduction of death compared with those in the melphalan arm.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters